StockData
Avalo Therapeutics, Inc. logo

Avalo Therapeutics, Inc. (AVTX) stock

AVTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/30
$7.13−0.24 (-3.26%)

Close on Nov 17, 2026Market cap $382.38MP/E –Yield –

Avalo Therapeutics total assets

Total assets on the balance sheet at the end of each period.

Avalo Therapeutics's total assets was $490.78M at Jun 30, 2026. For fiscal 2025 it was $116.46M, down 22.7% from the year before. Over ten years it grew 18.3% a year on average. The highest annual figure on record is $150.73M in fiscal 2024.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$116.46M-22.7%
FY2024Dec 31, 2024$150.73M+618.0%
FY2023Dec 31, 2023$20.99M-37.1%
FY2022Dec 31, 2022$33.37M-58.4%
FY2021Dec 31, 2021$80.21M+83.3%
FY2020Dec 31, 2020$43.76M+21.2%
FY2019Dec 31, 2019$36.11M-48.6%
FY2018Dec 31, 2018$70.25M+64.1%
FY2017Dec 31, 2017$42.81M+642.0%
FY2016Dec 31, 2016$5.77M-73.4%
FY2015Dec 31, 2015$21.66M+75.8%
FY2014Dec 31, 2014$12.32M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$490.78M+287.7%
Q1 FY2026Mar 31, 2026$99.89M-27.9%
Q4 FY2025Dec 31, 2025$116.46M-22.7%
Q3 FY2025Sep 30, 2025$125.10M+27.1%
Q2 FY2025Jun 30, 2025$126.58M+16.9%
Q1 FY2025Mar 31, 2025$138.52M+12.0%
Q4 FY2024Dec 31, 2024$150.73M+618.0%
Q3 FY2024Sep 30, 2024$98.46M+236.4%
Q2 FY2024Jun 30, 2024$108.31M+346.9%
Q1 FY2024Mar 31, 2024$123.73M+241.5%
Q4 FY2023Dec 31, 2023$20.99M-37.1%
Q3 FY2023Sep 30, 2023$29.27M-19.9%
Q2 FY2023Jun 30, 2023$24.24M-24.8%
Q1 FY2023Mar 31, 2023$36.24M-41.5%
Q4 FY2022Dec 31, 2022$33.37M-58.4%
Q3 FY2022Sep 30, 2022$36.55M-61.7%
Q2 FY2022Jun 30, 2022$32.22M-49.7%
Q1 FY2022Mar 31, 2022$61.90M-2.3%
Q4 FY2021Dec 31, 2021$80.21M+83.3%
Q3 FY2021Sep 30, 2021$95.36M+61.1%
Q2 FY2021Jun 30, 2021$64.09M-7.4%
Q1 FY2021Mar 31, 2021$63.35M+43.6%
Q4 FY2020Dec 31, 2020$43.76M+21.2%
Q3 FY2020Sep 30, 2020$59.19M+3.5%
Q2 FY2020Jun 30, 2020$69.20M+16.1%
Q1 FY2020Mar 31, 2020$44.12M-41.1%
Q4 FY2019Dec 31, 2019$36.11M-48.6%
Q3 FY2019Sep 30, 2019$57.19M-15.4%
Q2 FY2019Jun 30, 2019$59.62M-4.1%
Q1 FY2019Mar 31, 2019$74.87M+14.5%
Q4 FY2018Dec 31, 2018$70.25M+64.1%
Q3 FY2018Sep 30, 2018$67.61M+139.7%
Q2 FY2018Jun 30, 2018$62.15M+927.6%
Q1 FY2018Mar 31, 2018$65.36M+1735.6%
Q4 FY2017Dec 31, 2017$42.81M+642.0%
Q3 FY2017Sep 30, 2017$28.20M+194.3%
Q2 FY2017Jun 30, 2017$6.05M–
Q1 FY2017Mar 31, 2017$3.56M–
Q4 FY2016Dec 31, 2016$5.77M–
Q3 FY2016Sep 30, 2016$9.58M–

More Avalo Therapeutics figures

See a number that looks wrong?